Company ProfilePremium

GC Corporation

Company Profile Analysis

Ticker: 005250.KS주식회사 녹십자홀딩스

ESOMAR 23 Corporate BadgeISO Certifications Badge
GC Corporation - Company showcase

Year Founded & Workforce

1967

144 Employees

GC Corporation logo

GC Corporation Employee Contacts

41 verified contactsNames, job titles, seniority and locations

View Employee Contacts

GC Corporation Overview

GC Corp. is the listed pure holding company at the top of the GC Group, one of South Korea's oldest healthcare groups. Its main asset is a controlling stake in GC Biopharma (KRX: 006280), described as Asia's largest maker of protein therapeutics. GC Biopharma is a leading plasma fractionator and vaccine producer and owns the FDA-approved intravenous immunoglobulin ALYGLO. Around this core the holding company controls or invests in cell therapy (GC Cell), consumer and nutraceutical health (GC Wellbeing, which became a direct holding-company subsidiary in March 2026), US source-plasma collection (ABO Plasma), genomics (GC Genome), healthcare IT and services, and real-estate leasing. The company reports consolidated revenue of about KRW 2.45 trillion for FY2025. Profits have been thin or negative since 2023. The shares trade at roughly half of book value, which is typical of a Korean family-controlled holding company. The investment case rests on ALYGLO's ramp in the US, a turnaround at the subsidiaries, and capital-allocation discipline.

Disambiguation, Japanese GC Corporation (not profiled). The Japanese company was founded on 11 February 1921 in Tokyo as General Chemical Laboratory. It makes dental materials, including glass ionomer cements. The group has more than 3,200 employees and sales activities in more than 100 countries. Since December 2022 it has been run from GC International AG in Lucerne. It is privately held and family-owned, so no market data exists (Lucerne Business; Manufacturing Today; Dental Tribune).


What the company does. GC Corp. is a pure holding company (순수지주회사). It owns, finances and directs subsidiaries across biopharmaceuticals, cell therapy, diagnostics and genomics, consumer health, healthcare IT and services, and property leasing. It earns standalone income from dividends, brand royalties for the "GC" master brand, rental income and management fees. Its consolidated revenue is dominated by GC Biopharma.

Company self-description. Third-party summaries of company filings describe GC Corp. as a biotechnology holding company. Through its affiliates it provides plasma derivatives, prescription drugs, over-the-counter drugs, a Hunter syndrome drug, and vaccines for haemorrhagic fever, varicella, hepatitis B and influenza (Stoxray / S&P-derived profile; Morningstar).

Revenue model mix (consolidated). Butler.works compiles the mix from Q2 2026 filings:

The model is product-led: manufactured plasma derivatives, vaccines and drugs, plus resale of in-licensed products such as Paxlovid distribution in Korea. Service revenue comes from diagnostics, genomic testing, cell-therapy CDMO work and healthcare IT. Subscription-type revenue is modest and sits mainly in healthcare IT. Licensing revenue is episodic and arises from out-licensing of pipeline assets.

Value-chain position. GC is vertically integrated in plasma. It collects source plasma in the US through ABO Plasma and in Korea through the national blood system. It fractionates plasma at Ochang, Korea, and markets finished products in Korea, the US, China, Latin America and the Middle East. In vaccines it runs the full chain from bulk antigen production (Hwasun, Korea) to finished doses. It also sells bulk influenza antigen and finished flu vaccine to international agencies and southern-hemisphere markets.

Customer types. Customers include hospitals and clinics in Korea; specialty pharmacies, infusion centres and group purchasing organisations in the US (ALYGLO); government and NIP buyers for vaccines; international procurement agencies; pharmacies and consumers for OTC products and nutraceuticals; other plasma fractionators (ABO Plasma sells source plasma to third parties); and biotech clients for CDMO and testing.

End-markets. The company serves:

  • Immunology and plasma therapeutics (IVIG, albumin, haemophilia factors)

  • Vaccines (influenza, varicella, Td/Tdap, hepatitis B, Hantaan virus)

  • Rare diseases (Hunter syndrome)

  • Primary-care prescription drugs in Korea

  • Consumer health

  • Cell therapy (NK and CAR-NK)

  • Clinical diagnostics and genomics

  • Healthcare IT

Analyst characterisation. GC Corp. is best understood as a leveraged call on GC Biopharma's plasma franchise, wrapped in a holding-company discount. GC Biopharma provided about 81% of consolidated revenue in FY2025 (KRW 1,991.3 bn of KRW 2,451.5 bn). The remaining subsidiaries add revenue but have dragged on earnings, through losses at GC Cell, start-up losses at ABO Plasma, and impairments. The group's strategic direction since 2023 has been to concentrate on high-margin global products (ALYGLO, Hunterase, Barycela) while restructuring loss-making units. The March 2026 transfer of GC Wellbeing from GC Biopharma to the holding company shows the holding company acting as the group's internal bank.

Strategy

Stated themes from public statements:

  • Becoming a "global leader in the health industry" (Chairman, AGM).

  • "Selection and concentration" on plasma derivatives and high-margin global products (GC group statements, Apr 2026).

  • Improving subsidiary efficiency and earnings structure (GC Biopharma, Jan 2025).

  • Portfolio reshaping at the holding company to raise corporate value (GC Group, Mar 2026).

Medium-term guidance. GC Biopharma's FY2025 operating-profit guidance was cut to the KRW 60 bn range from KRW 70–80 bn. The outcome was about KRW 69 bn. GC Corp. does not publish consolidated guidance in sources reviewed. ESG commitments and quantified cost programmes are not publicly disclosed in sources reviewed.

Products & Services

Note on completeness: GC Biopharma markets well over 100 SKUs. Pricing is not publicly disclosed for any of these products.

Plasma derivatives (GC Biopharma)

ProductDescriptionTarget customerLaunch / statusNotes
ALYGLO (immune globulin intravenous, human-stwk, 10% liquid; IVIG-SN 10%)IVIG for primary humoral immunodeficiencyUS immunologists, infusion centres, specialty pharmacyFDA approval Dec 2023; US launch Jul 2024FY2025 US sales above KRW 150 bn; Q2 2026 KRW 40.5 bn; FY2026 target USD 150 M. A subcutaneous (SC) version is in development, with a BLA targeted for 2031
IVIG-SN (domestic and export IVIG)Immune globulin 5% / 10%Hospitals in Korea and export marketsMarketedKawasaki disease (mucocutaneous lymph node syndrome) indication noted in profiles
AlbuminPlasma volume expanderHospitals; export (China a key market historically)MarketedChina exports drove plasma growth historically (Biospectator)
Green-VIII injPlasma-derived factor VIII for haemophilia AHaemophilia treatment centresMarketedNamed in Morningstar profile
Antithrombin and other plasma proteinsSpecialty plasma proteinsHospitalsMarketedNamed in Craft profile

Rare disease

ProductDescriptionTarget customerStatusNotes
Hunterase (idursulfase-beta)Enzyme replacement therapy for Hunter syndrome (MPS II)Rare-disease centres in Korea, MENA, LatAm, AsiaMarketed; ICV (intracerebroventricular) formulation addedFY2025 revenue KRW 74.4 bn (+20%); additional ICV approvals in Japan, Russia and Peru (Alphadistill)

Vaccines

ProductDescriptionTarget customerStatusNotes
GC Flu (influenza; quadrivalent moving to trivalent)Seasonal influenza vaccine; bulk antigen also soldKorean NIP and private market; southern-hemisphere export; international agenciesMarketedShift from quadrivalent to trivalent cut selling prices in 2025 (Hana/Eugene research); Q2 2026 bulk antigen sales pushed into Q3 by delays in WHO strain reference material
Barycela (varicella)Live attenuated chickenpox vaccineNIP and private paediatric market; exportMarketedFY2025 revenue KRW 32.1 bn (more than doubled)
HantavaxHantaan virus (haemorrhagic fever) vaccineMilitary and high-risk groupsMarketedNamed in Stoxray profile
Hepatitis B vaccineRecombinant hepatitis BNIP; exportMarketedNamed in Stoxray profile
Td/Tdap vaccinesTetanus-diphtheria (pertussis)NIPMarketedGeneral record; not re-verified

Prescription (ETC) and commercial-partner products

ProductDescriptionNotes
Paxlovid (Pfizer COVID-19 antiviral) distribution in KoreaCommercial distributionEstimated at about KRW 70.3 bn in Q3 2025 (SK Securities preview); lower-margin "merchandise" revenue
In-licensed and co-promoted ETC portfolio (cardiometabolic, others)Primary-care drugs in Korea—

OTC and consumer healthcare

ProductDescriptionNotes
Acustop CataplasmaTopical pain-relief patchMorningstar profile
Zenol Cool TypeTopical analgesic patchMorningstar profile
GC Wellbeing placenta-derived injections (e.g. Laennec-type products) and nutraceuticalsNutritional and wellness injections, supplementsGC Wellbeing FY2025 revenue KRW 164.7 bn; individual brand names not re-verified

Cell therapy and CDMO (GC Cell)

OfferingDescriptionStatus
AlloNK (allogeneic NK cell programme, partnered with Artiva)NK cell therapy in combination studiesAlphadistill reports entry into global Phase 3
Immuncell-LCAutologous T-cell therapy for liver cancer (Korea)Marketed in Korea (general record; not re-verified)
Cell-therapy CDMO and specimen testingContract manufacturing; central lab and testing servicesRevenue included in GC Cell's KRW 165.5 bn

Plasma collection (ABO Plasma)

AssetDescriptionStatus
7 FDA-licensed US plasma centres (California: Calexico and one other; Utah: Orem and one other; New Jersey: Cherry Hill, Glassboro; Texas: Laredo)Source-plasma collection, for supply to ALYGLO and for third-party sale8th centre (Eagle Pass, TX) planned; target is 80% of ALYGLO plasma self-sourced by 2028

Diagnostics, genomics and healthcare IT

OfferingDescriptionStatus
GC Genome genetic testingGenomic diagnostics, including NIPT and cancer screening9M FY2025 revenue KRW 23.5 bn (+26%) and turned profitable; IPO planned for 2028
Healthcare IT / medical servicesEMR and clinic software, medical servicesAbout 9% of GC Corp. consolidated revenue (Q2 2026)

Financial Narrative

Basis. These are GC Corp. consolidated K-IFRS figures. Primary sources are Butler.works (compiled from DART) and Stoxray (S&P-sourced). FY2024 revenue is derived from FY2025 revenue and the reported +11.2% growth.

Margins and growth (computed)

FY2021 growth is computed against FY2020 revenue of KRW 1,719.3 bn (Stoxray). The four-year revenue CAGR from FY2021 to FY2025 is about 7.4%.

Core subsidiary — GC Biopharma consolidated

Sources: Dailypharm (FY2021); Biospectator (FY2023, -4.9% YoY, which implies the FY2022 base); Kiwoom research, Jan and Apr 2026 (FY2023–FY2025 detail).

Discrepancy: Dealsite (26 Jan 2026) printed FY2025 operating income as KRW 37.0 bn, up 115.3%. A 115.3% increase on KRW 32.1 bn equals about KRW 69.1 bn, which matches Kiwoom. KRW 37.0 bn appears to be the size of the increase, not the level. Dealsite also reported FY2025 net loss of KRW 26.1 bn against Kiwoom's KRW 29.7 bn; these are likely the preliminary and final figures.

GC Biopharma margins (computed):

Balance sheet, cash flow and ratios

Note on the cash-flow sequence: Stoxray lists cash from operations FY2020 KRW 38.1 bn, FY2021 KRW 103.8 bn, FY2022 KRW 97.2 bn, FY2023 KRW -39.7 bn. Alignment to fiscal years is inferred from the matching net-income series.

The following items are not publicly disclosed in sources reviewed:

  • Total assets, total debt (short / long split), net debt and working capital at GC Corp. consolidated level

  • Capex, dividends paid and buybacks

  • ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle

These require the FY2025 DART business report.

Commentary on trends and drivers.

  1. Top line. Revenue has compounded at roughly 7% a year, with one flat year (FY2023) that followed the post-COVID fall in vaccine and testing demand. FY2025 was the strongest year (+11.2%). It was driven by ALYGLO's first full commercial year in the US, Hunterase and Barycela, and the first-time consolidation of ABO Plasma.

  2. Profit collapse and partial recovery. Operating profit fell from KRW 86.2 bn (FY2021) to losses in FY2023–FY2024, then recovered to KRW 36.2 bn in FY2025. The causes were cost-of-goods inflation in plasma, losses at GC Cell and other subsidiaries, and lower-margin merchandise revenue. The FY2025 recovery mirrors GC Biopharma's operating-profit doubling.

  3. Below-the-line drag. Net income has been negative in three of the last three years. Causes include rising interest costs at GC Biopharma (Eugene, Aug 2024), financial-asset valuation losses, and non-cash impairments (GC Cell goodwill in FY2025). This is the central reason the shares trade at about 0.5x book.

  4. Working capital intensity. GC Biopharma's inventory rose by about 73% between FY2023 and FY2025 (KRW 516 bn to KRW 892 bn). That reflects plasma stock-building for ALYGLO and is consistent with negative free cash flow per share every year.

  5. Inflection watch. Consensus (Kiwoom, Apr 2026) expected GC Biopharma net income to turn positive in FY2026 at KRW 36.8 bn. The weak Q2 2026 makes that dependent on the second half of the year.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationship to GC Corp.BusinessListing

GC Biopharma Corp. (GC녹십자)

Core subsidiary. The Holdings group (GC Corp. and 12 related parties) owns about 51.4%

Plasma derivatives, vaccines, prescription drugs, OTC drugs

KOSPI 006280

GC Wellbeing (GC녹십자웰빙)

Directly held, 34.5% (largest shareholder) since 31 Mar 2026; previously partly held via GC Biopharma

Nutraceutical injections (placenta-derived products and others), health supplements

KOSDAQ (listed)

GC Cell (지씨셀)

Consolidated by GC Biopharma

NK and CAR-NK cell therapy, cell-therapy CDMO, specimen testing

KOSDAQ

ABO Plasma (formerly ABO Holdings)

100% owned via GC Biopharma's investment vehicle

US source-plasma collection (7 FDA-licensed centres)

Unlisted

GC Genome

Group affiliate

Genomic diagnostics; IPO targeted for 2028

Unlisted

Lymphotec (Japan)

Shares moved from GC Cell to GC Corp. and GC Genome

Japanese cell-therapy business

Unlisted

GC Care / healthcare IT units

Group affiliates

Medical services and healthcare IT systems (about 9% of consolidated revenue)

—

Mogam Institute for Biomedical Research

Related non-profit foundation; historically a major shareholder of Holdings

R&D foundation

—

Revenue by Segment

Division (KRW Bn)FY2023FY2024FY2025

Plasma derivatives revenue KRW Bn

424.6478.3560.2

Vaccines revenue KRW Bn

265.9256.0300.6

Prescription drugs (ETC) revenue KRW Bn

395.7420.0479.8

OTC and consumer healthcare revenue KRW Bn

123.7121.7119.7

Consolidated subsidiaries revenue KRW Bn

416.8403.9—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Revenue

DivisionFY2024 YoY %FY2025 YoY %FY2025 share of standalone divisions %

Plasma derivatives

12.717.138.0

Vaccines

-3.717.420.4

Prescription drugs

6.114.232.5

OTC / consumer

-1.6-1.68.1

Subsidiary Metric Details

Subsidiary metric (KRW Bn)FY2025

GC Cell revenue

165.5

GC Cell operating profit

-13.8

GC Wellbeing revenue

164.7

GC Wellbeing operating profit

17.3

GC Genome revenue 9M

23.5

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Revenue KRW Bn

1,840.62,079.62,057.92,204.62,451.5

Operating income KRW Bn

86.271.2-16.4-10.736.2

Net income (total) KRW Bn

127.758.9-72.8-11.1-41.8

Basic EPS (controlling) KRW

1,222709-1,210529-1,531

Revenue per share KRW

40,69444,92045,99748,54853,993

Dividend per common share KRW

——300——

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY %

7.013.0-1.07.111.2

Operating margin %

4.73.4-0.8-0.51.5

Net margin %

6.92.8-3.5-0.5-1.7

Financial Analysis — Revenue KRW Bn

MetricFY2021FY2022FY2023FY2024FY2025

Revenue KRW Bn

1,537.81,710.41,626.61,679.91,991.3

Operating income KRW Bn

73.781.034.432.169.1

EBITDA KRW Bn

——110.3113.1156.8

Pre-tax income KRW Bn

———-41.1-35.3

Net income KRW Bn

——-19.8-42.6-29.7

Net income attributable to controlling KRW Bn

———-26.3-4.7

EPS KRW

———-2,249-400

Margin Analysis (%) (FY2023–FY2025)

MetricFY2023FY2024FY2025

Operating margin %

2.11.93.5

EBITDA margin %

6.86.77.9

Financial Analysis — Cash flow from operations

ItemLatest availableSource

Cash flow from operations (GC Corp. consolidated)

KRW -39.7 bn (FY2023); positive in FY2021 (KRW 103.8 bn) and FY2022 (KRW 97.2 bn)

Stoxray. Sequence alignment inferred; see note

Free cash flow per share

Negative every year FY2010–FY2025; FY2025 KRW -2,770; TTM KRW -1,169

roic.ai

GC Biopharma inventory

KRW 516.2 bn (FY2023), KRW 746.6 bn (FY2024), KRW 891.6 bn (FY2025)

Kiwoom

GC Biopharma controlling equity

KRW 1,300.2 bn (FY2023), KRW 1,252.6 bn (FY2024), KRW 1,217.5 bn (FY2025)

Kiwoom

GC Biopharma cash and equivalents (standalone, end FY2025)

About KRW 0.8 bn standalone; Craft reports KRW 49.4 bn at the consolidated level

Dailypharm; Craft

GC Corp. treasury stock

4.37% of shares

Butler.works

ROE (GC Corp., TTM)

-13.42% (Wisesheets, Aug 2026) vs -5.06% (StockHub)

Sources conflict

P/B

about 0.54x

Butler.works; StockHub

Revenue by Region

Overseas line (KRW Bn)FY2024FY2025

ALYGLO United States revenue KRW Bn

50150

Region Overview

RegionPrincipal products / activitiesTrendReason

United States

ALYGLO (IVIG); ABO Plasma source-plasma sales

Fastest-growing

ALYGLO launch Jul 2024; FY2026 target USD 150 M; 7 licensed plasma centres

South Korea

All segments; dominant share of revenue

Mature, low growth

Price controls on NIP vaccines; flu vaccine shift to trivalent lowered prices

China

Albumin, IVIG exports

Volatile

Historically strong albumin exports (Biospectator, 2022)

Middle East / North Africa, Latin America, CIS

Hunterase, plasma products, flu vaccines

Growing

New Hunterase ICV approvals in Japan, Russia, Peru; tender-driven vaccine sales

Southern hemisphere / international agencies

Influenza vaccine (finished and bulk)

Seasonal, lumpy

Q2 2026 bulk sales delayed to Q3 by WHO strain-reference delays

Japan

Lymphotec (cell therapy); Hunterase ICV

Early stage

Group plans full-scale entry into Japanese cell therapy via GC Corp.

Share Price History

DatePriceSource

26 Dec 2024

17,780

Stoxray

17 Apr 2026

14,560 (52-week range 12,790–17,700)

Investing.com

Aug 2026

9,960

Wisesheets

Q3 2026

9,810–10,050 (52-week range 9,490–18,010)

Butler.works; StockHub

Valuation Multiples

MultipleGC Corp.

P/E

Not meaningful (losses)

P/B

about 0.54x

P/S

about 0.19x (market cap about KRW 465 bn / FY2025 revenue KRW 2,451.5 bn)

Dividend yield

about 3.06%

Capital Markets

MetricFY2016FY2023

Common DPS KRW

300300

Analyst Conclusions

Management guidance. GC Biopharma targets FY2026 ALYGLO revenue of USD 150 M and expects earnings weighted to the second half (the delayed flu bulk shipped in July; Hunterase exports concentrated in H2). ABO Plasma aims to halve its operating loss. No GC Corp. consolidated guidance was found.

Consensus. Kiwoom (Apr 2026) forecast GC Biopharma FY2026 revenue of KRW 1,993.1 bn, operating profit of KRW 71.1 bn and net income of KRW 36.8 bn; for FY2027, revenue of KRW 2,124.6 bn and operating profit of KRW 96.4 bn. No consensus exists for GC Corp.

Bull case

  1. ALYGLO scaling toward KRW 300 bn by 2027 with 80% self-sourced plasma could lift group margins from a low base (FY2025 operating margin 1.5%).

  2. At about 0.5x book and about 0.2x sales, modest profit normalisation could re-rate the stock.

  3. Monetisation options: GC Genome IPO (2028), and an earnings swing from GC Cell, which posted Q2 2026 net income.

Bear case

  1. Three consecutive net losses and negative FCF show that growth has not converted into cash.

  2. H1 2026 GC Biopharma operating profit fell 61%, and guidance credibility is weak after the FY2025 cut.

  3. Holding-company discount, family control and pay controversy limit re-rating potential.

Catalysts and monitorables (next 12 months)

  • Q3 2026 results (late Oct / early Nov 2026): flu bulk and Hunterase recognition

  • Quarterly ALYGLO run-rate against the USD 150 M target

  • Eagle Pass centre licensing

  • ABO Plasma loss trajectory

  • FY2026 dividend decision

  • Any Korea Value-up disclosure or buyback

  • Succession signals

Analyst verdict. GC Corp. is a deep-value but low-quality holding company. Its fortunes are tied almost entirely to GC Biopharma's attempt to become a credible US plasma player. The strategic logic is sound. ALYGLO is a real asset: an FDA-approved IVIG with more than KRW 150 bn of first-full-year sales. Buying ABO Plasma addresses the binding constraint in the business, which is access to plasma. Hunterase and Barycela give the vaccine and rare-disease franchises genuine high-margin products.

Execution and capital efficiency are the problem. Over five years revenue grew about 33%, yet operating profit fell by more than half and the company lost money in each of the last three years. Free cash flow has been negative throughout. Working capital, especially plasma inventory, has absorbed the growth. The holding company has used its cash to support subsidiaries, as in the March 2026 Wellbeing purchase, rather than to reward minority shareholders. Paying the chairman more than KRW 2.4 bn in a loss year shows why governance-sensitive investors apply a steep discount.

The valuation already reflects much of this. At about 0.54x book and 0.2x sales, with a roughly 3% dividend yield, the shares price in a stagnant outcome. The asymmetry depends on whether the second half of 2026 delivers the recovery management has promised. If ALYGLO stays on track for USD 150 M and GC Biopharma returns to positive net income in FY2026, consolidated profits could move from losses to positive territory, and the discount to net asset value could narrow. If it does not, GC Corp. remains a value trap.

The position is best described as speculative accumulation for investors who can monitor quarterly ALYGLO data and Korean governance reform. It is not suitable as a core holding. The deciding evidence will be the Q3 and Q4 2026 results and any formal shareholder-return policy.


SOURCES CONSULTED

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundFY2025 total pay (KRW Bn)

Huh Il-seop (허일섭)

Chairman, GC Corp.; also paid by GC Biopharma

Chairman since 2009; youngest son of Hanil Cement founder Huh Chae-kyung; largest shareholder of GC Corp.

2.413 total (1.193 from GC Corp. + about 1.220 from GC Biopharma)

Huh Yong-joon (허용준)

CEO and President, GC Corp.

Joined 2003; served in management planning and sales planning, then head of management control (VP); CEO from Mar 2017; Yonsei University; MBA, University of Wisconsin

2.125

Huh Eun-chul (허은철)

President and CEO, GC Biopharma

Son of the late Huh Young-sup; brother of Huh Yong-joon

1.159 (from GC Biopharma)

Park Yong-tae (박용태)

Vice Chairman, inside director, GC Corp.

Long-time ally of the chairman; re-elected at the 2017 AGM

—

Huh Jin-sung (허진성)

Executive, GC Corp. strategy / growth strategy

Eldest son of the chairman

—

Governance Overview

ItemDetail

Chair / CEO separation

Separate roles: Chairman Huh Il-seop and CEO Huh Yong-joon are both registered inside directors and co-representatives (TheVC lists both as 대표)

Governance flags

(1) Family control with two branches: the chairman's branch and the late co-founder's sons. (2) Executive pay paid while the company is loss-making (Mar 2026 press criticism). (3) Holding company funds subsidiaries through related-party transactions (Wellbeing share purchase, support for GC Care and GC Cell M&A)

Major Shareholders

HolderStakeAs ofSource

Huh Il-seop

12.16%

Sep 2022

Dealsite

Mogam Institute for Biomedical Research

8.73%

Dec 2020

Dailypharm

Huh Yong-joon

about 2.65%

2,018

Bizhankook

Huh Eun-chul

about 2.51%

2,018

Bizhankook

Huh Jin-sung

0.69%

Sep 2022

Dealsite

Huh Jin-hoon

0.64%

Sep 2022

Dealsite

Treasury shares

4.37%2,026

Butler.works

National Pension Service

—

Jul 2026

TheVC

Largest-shareholder group, total

—

Feb 2014

eToday

Competitive Landscape

Competitors by Segment

SegmentCompetitorsPositioning of GC

Global plasma / IVIG

CSL Behring (Privigen, Hizentra), Takeda (Gammagard, HyQvia), Grifols (Gamunex-C), Octapharma (Octagam), Kedrion, LFB, Bio Products Laboratory

A small challenger in the US; ALYGLO is a late entrant competing on supply and price

Korean plasma

SK Plasma

Domestic leader

Korean vaccines

SK bioscience, Boryung Biopharma, Il-Yang, plus multinationals (Sanofi, GSK)

Leading local flu and varicella supplier

Rare disease (MPS II)

Takeda (Elaprase), JCR Pharmaceuticals (Izcargo, Japan), Denali (pipeline)

Strong in emerging markets; ICV niche

Korean prescription drugs

Yuhan, Chong Kun Dang, Hanmi, Daewoong, Dong-A ST

Mid-tier

Cell therapy

Global NK / CAR-T developers

Early stage

Korean holding-company peers

Chong Kun Dang Holdings, Dong-A Socio Holdings, Hansol Holdings, Huons Global

Similar discount structure

Competitor Detail

MetricGC Corp. (FY2025)

Revenue

KRW 2,451.5 bn

Operating margin

1.5%

Revenue growth

11.2%

R&D intensity

about 10% (GC Biopharma FY2024)

Recent Developments

--

Company Snapshot

144

Employees

1967

Founded

Gyeonggi-do, South Korea

Headquarters

SWOT Analysis

Strengths

  • ALYGLO has US FDA approval and passed KRW 150 bn in revenue in its first full year (FY2025).
  • Vertical integration through 7 FDA-licensed ABO plasma centres, targeting 80% self-supply by 2028.
  • Hunterase revenue of KRW 74.4 bn (+20% in FY2025) with new ICV approvals in Japan, Russia and Peru.
  • Barycela revenue more than doubled to KRW 32.1 bn in FY2025.
  • Revenue has grown at about a 7.4% CAGR (FY2021–FY2025) to KRW 2.45 trn.
  • Stable control: the Holdings group owns 51.4% of GC Biopharma.

Weaknesses

  • Consolidated net losses in FY2023, FY2024 and FY2025 (KRW -72.8 bn, KRW -11.1 bn, KRW -41.8 bn).
  • Operating margin of only 1.5% in FY2025.
  • Free cash flow per share negative every year since 2010.
  • GC Biopharma inventory up 73% in two years to KRW 891.6 bn.
  • GC Cell operating loss of KRW 13.8 bn plus goodwill charges.
  • Repeated guidance misses (FY2025 operating-profit guidance cut in Nov 2025; Q2 2026 operating profit down 93.8%).

Opportunities

  • ALYGLO trajectory: company targets above KRW 200 bn in 2026 and above KRW 300 bn in 2027.
  • ALYGLO SC (BLA 2031) would enter the fast-growing subcutaneous IG segment.
  • ABO Plasma: 8th centre in Eagle Pass and third-party plasma sales.
  • GC Genome IPO (2028) could crystallise value.
  • Japanese cell-therapy market entry via Lymphotec.
  • Korean "Value-up" programme pressure could narrow the holding-company discount (P/B about 0.54x).

Threats

  • Large-incumbent pricing power in US IG (CSL, Takeda, Grifols).
  • WHO strain-reference delays already shifted Q2 2026 revenue (precedent).
  • Flu vaccine price erosion from the quadrivalent-to-trivalent switch.
  • Higher interest costs (cited as a driver of the 2024 net losses).
  • Governance scrutiny: KRW 2.4 bn chairman pay during losses.
  • Succession uncertainty between family branches.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
13–14 May 2025Calexico, CA plasma centre FDA-approved; all 6 ABO centres licensedPlasma sales can begin at every centre
Q2 2025Three more ABO centres approved during the quarterRevenue ramp starts
Q3 2025ABO introduces a new plasma collection system; KRW 3–4 bn one-off costLifts efficiency; short-term margin hit
20 Oct 2025SK Securities Q3 preview: flu vaccine price cut (quadrivalent to trivalent), lower Hunterase and Barycela shipmentsEarnings risk flagged
4 Nov 2025GC Biopharma Q3 2025: revenue KRW 609.5 bn (+31%), operating profit KRW 29.2 bn (-26%); FY guidance cut to KRW 60 bn rangeNegative revision
19 Jan 2026Kiwoom preview: Q4 operating profit about KRW 2.4 bn; FY2026 operating profit forecast KRW 94.9 bnPositive inflection expected
26 Jan 2026GC Biopharma FY2025 preliminary: revenue KRW 1,991.3 bn (+18.5%); Q4 turns profitable for the first time in about 8 years; ALYGLO above KRW 150 bnTurnaround evidence
26 Jan 2026GC Cell FY2025 revenue KRW 165.5 bn; loss narrowed 31%; goodwill chargeSubsidiary drag easing
Feb 2026GC Corp. FY2025: revenue KRW 2,451.5 bn (+11.2%); operating profit KRW 36.2 bn; net loss KRW 41.8 bnThird straight net loss
18 Mar 2026Pay disclosures: Chairman KRW 2.41 bn, CEO Huh Yong-joon KRW 2.13 bn despite lossesGovernance criticism
Late Mar 2026AGMs of GC Corp. and affiliatesRoutine
31 Mar 2026GC Corp. buys GC Biopharma's GC Wellbeing stake for KRW 50.5 bnHolding-company portfolio reshaping
6–7 Apr 2026Press: GC Biopharma to put proceeds into Ochang expansion and ALYGLO SCCapital reallocation
17 Apr 2026GC Corp. share price KRW 14,560; 52-week range KRW 12,790–17,700Reference point
20 Apr 2026Kiwoom cuts GC Biopharma FY2026 forecast to revenue KRW 1,993.1 bn, operating profit KRW 71.1 bn (Wellbeing deconsolidation)Estimate cut
Q1 2026GC Biopharma Q1: revenue KRW 440.5 bn (+15% YoY), operating profit KRW 10.7 bnIn line
2026 (Q2)GC Biopharma investor day; ALYGLO SC unveiled with a 2031 BLA targetLifecycle strategy
2026Laredo, TX plasma centre FDA-approved; all 7 centres licensed; Eagle Pass plannedUS plasma scale
9 Jul 2026GC Corp. files correction to a subsidiary's equity-disposal disclosureFiling
15 Jun 2026Large-holding and major-shareholder change filings for GC Corp.Ownership movement
31 Jul 2026GC Biopharma Q2 2026: revenue KRW 421.2 bn (-15.8%), operating profit KRW 1.7 bn (-93.8%), net income KRW 1.1 bnSharp miss; shares under pressure
31 Jul 2026GC Cell Q2 2026: revenue KRW 41.6 bn; net income KRW 2.2 bn, first profit in 2 yearsSubsidiary improvement
31 Jul 2026ALYGLO Q2 2026 revenue KRW 40.5 bn (+10% QoQ); FY2026 target USD 150 M reaffirmedCore franchise intact
Jul 2026Delayed flu bulk antigen fully shipped; to be booked in Q3 2026Second-half earnings catalyst
14 Aug 2026GC Corp. H1 2026 semi-annual report filedFiling
Aug–Sep 2026GC Corp. shares fall to about KRW 9,500–10,000 (52-week low KRW 9,490); TTM ROE about -13%Valuation near 0.5x book

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2023–FY2025): Plasma derivatives revenue KRW bn rose from KRW 424.6 Bn in FY2023 to KRW 560.2 Bn in FY2025.
GC Corporation — Revenue by Segment (FY2023–FY2025)
Series (KRW Bn)FY2023FY2024FY2025
Plasma derivatives revenue KRW bn424.6478.3560.2
Vaccines revenue KRW bn265.9256300.6
Prescription drugs (ETC) revenue KRW bn395.7420479.8
OTC and consumer healthcare revenue KRW bn123.7121.7119.7
Consolidated subsidiaries revenue KRW bn416.8403.9—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.